Which non-oral dosage forms can be evaluated on this platform?

Our platform supports a broad range of non-oral formulations including topical creams, ointments, gels, transdermal patches, buccal films, ophthalmic solutions, nasal sprays, and parenteral depot systems (microspheres, liposomes, in situ gels). Each formulation type requires a tailored method design, which is scoped during initial consultation.

What analytical techniques are used to quantify drug release and permeation?

We typically use HPLC-UV or LC-MS/MS for quantitation, depending on the drug's physicochemical properties and required sensitivity. Method development follows ICH guidelines and includes specificity, linearity, precision, and recovery validation. For highly potent or poorly UV-absorbing compounds, LC-MS/MS is preferred.

How do you handle poorly soluble drugs in IVRT/IVPT studies?

For poorly soluble compounds, we optimize the receptor medium with appropriate co-solvents or surfactants to maintain sink conditions without harming the membrane integrity. Alternative approaches such as sample-and-separate or continuous flow cells can also be applied. All modifications are documented and evaluated for their impact on release kinetics.

Can the data support regulatory submissions such as IND, NDA, or ANDA?

Yes, our study reports are designed to align with FDA and EMA expectations for in vitro release and permeation data. We follow the relevant guidance documents (e.g., SUPAC-SS, FDA IVRT guidance) and provide a clear description of method validation, experimental conditions, and data interpretation. Each project’s suitability for a specific regulatory pathway is discussed during scoping.

What is typical project turnaround time?

Turnaround time is project-dependent and defined during scoping. We aim to provide an initial study plan within one week of receiving formulation samples and target compound information. Execution timelines depend on method development complexity and number of test conditions.

Do you provide consultation on IVIVC model development?

Yes, we can support the generation of in vitro release and permeation data that may be used for IVIVC modeling. However, the correlation itself is typically performed by the client or a partner modeling team. We provide the raw in vitro results, including detailed time-point profiles, necessary for such analysis.

Services

Online Inquiry

Name *

Email *

Subject *

Phone

Your Message

How Did You Hear About Us

Non-Oral Formulation In Vitro Release and Permeability Evaluation Platform

Non-Oral Formulation

Obtain validated in vitro release and permeation data for injectable, topical, and other non-oral dosage forms using methods aligned with regulatory expectations.

In vitro release testing (IVRT) for semisolid, suspension, and depot formulations
In vitro permeation testing (IVPT) using human or animal skin models
Analytical method development and validation (HPLC, LC-MS/MS)
Data packages suitable for IND/NDA/ANDA submissions

Validate Your Formulation

Why standardized in vitro data matters for non-oral drugs

Non-oral formulations require specialized release and permeability assays to predict in vivo performance and support regulatory filings. Our platform delivers reproducible, methodical evaluation across diverse dosage forms.

Regulatory-ready data for topical, transdermal, parenteral, and mucosal products
Mechanistic understanding of formulation release and barrier transport
Formulation screening support during early and late-stage development
Integration with biopharmaceutical profiling (solubility, stability, IVIVC)

Reproducible

Regulatory-Aligned

Project-Specific

Scientific Approach

Tailored release and permeability evaluation for non-oral formulations

We combine standard IVRT/IVPT methods with project-specific adaptations to address solubility, dosage form complexity, and intended regulatory pathway.

Core IVRT/IVPT Platform

Our in vitro release and permeability testing follows pharmacopoeia-relevant methods (e.g., vertical diffusion cell, flow-through cell) and can be adapted for emulsions, liposomes, microparticles, films, and other non-oral systems.

IVRT: sample-and-separate, continuous flow, or dialysis membrane as appropriate
IVPT: human cadaver/animal skin or synthetic membranes based on formulation
Analytical support: HPLC, LC-MS/MS, and validated impurity/leachables testing

Biopharmaceutical Integration

We integrate release and permeation data with solubility, stability, and formulation characterization (particle size, viscosity, polymorph) to build a complete in vitro profile for candidate selection and regulatory bridging.

Correlation between IVRT/IVPT and key physicochemical properties
Support for IVIVC model development when appropriate
Project-specific study design for poorly soluble or degraded actives

Method Quality

Assays are developed and validated for specificity, linearity, precision, and robustness per ICH Q2(R1) or modified guidelines for non-oral products.

Statistical Rigor

Replicate design, sample size determination, and data analysis (e.g., flux, lag time, cumulative release) follow FDA/EMA guidance for IVRT/IVPT studies.

Regulatory Narrative

We prepare detailed study reports that include raw data, analytical conditions, and interpretation to facilitate regulatory interactions and submission dossiers.

Deliverables

Comprehensive data packages for informed decisions

Every project delivers method-specific reports with raw data, curve analysis, and a summary of performance against acceptance criteria.

Data Deliverables

Cumulative release profiles and release rate (if applicable)
Permeability coefficients, flux, and lag time
Method validation summary (linearity, precision, recovery)
Raw data tables and chromatograms (PDF and electronic format)

Reporting & Support

Customized study plan and protocol for each formulation
Final report with methods, results, and conclusion
Consultation on study design and data interpretation
Regulatory support documents (e.g., dissolution method development report)

Service Scope

Parameter-driven project definition

The scope is defined case by case during consultation. The table below illustrates typical parameters and options available.

Parameter	Typical Project Scope
Formulation type	Topical, transdermal, parenteral (solution, suspension, liposome, microparticle), buccal, ophthalmic, nasal
Test method	IVRT (vertical diffusion cell, flow-through cell), IVPT (Franz cell, open chamber), sample-and-separate
Membrane	Human cadaver skin, porcine skin, synthetic membrane (e.g., cellulose acetate), excised mucosa
Receptor medium	PBS, simulated biological fluid, with/without surfactant or solubilizer; temperature and pH controlled
Analytical technique	HPLC-UV, LC-MS/MS, or UV-Vis spectrophotometry (validated per study need)
Endpoints	Cumulative release, release rate, flux, lag time, permeability coefficient (Kp), retention in skin/depot
Number of replicates	3–6 per test condition (determined by expected variability)
Study duration	Defined by release kinetics (hours to days); scoped per project

Workflow

From scoping to deliverable in five steps

Each project follows a structured yet flexible process to ensure the method matches the formulation's properties and regulatory context.

Project Scoping

We review your formulation, intended route, and regulatory goal to define the appropriate IVRT/IVPT method, membrane, receptor fluid, and sampling schedule.

Method Development & Feasibility

We develop or adapt the analytical method (HPLC, LC-MS/MS) and confirm solubility, stability, and sink conditions in the receptor medium.

Study Execution

IVRT/IVPT experiments are performed according to the validated protocol, with temperature control, sink conditions, and timed sampling.

Data Analysis & QC

Release profiles, flux, and permeability parameters are calculated. Outliers are assessed, and method performance is checked against acceptance criteria.

Reporting & Delivery

A comprehensive report is compiled, including raw data, graphs, statistical summary, and a narrative of findings for your development team or submission.

Applications

Supporting development across non-oral dosage forms

Our platform addresses key questions during formulation screening, bridging, and bioequivalence assessment for a range of non-oral products.

Optimize local delivery and systemic absorption

IVRT and IVPT are commonly used to compare formulations, assess batch-to-batch consistency, and support Q3 characterization for topical dermatologic and transdermal systems.

Release comparison between prototype formulations
Permeation flux evaluation across human or animal skin
Bioequivalence support for generic dermatologic products

Characterize release from long-acting injectables

For microspheres, liposomes, and in situ forming depots, accelerated and real-time release methods help predict in vivo release and ensure product quality.

Real-time and accelerated release profiling for PLGA microspheres
IVIVC feasibility for extended-release parenteral formulations
Stability-indicating release method development

Support ANDA submissions with in vitro data

Regulatory agencies often require comparative IVRT/IVPT data to demonstrate sameness between generic and reference formulations for non-oral products.

Q1/Q2/Q3 comparability studies for topical generics
IVPT for transdermal and mucosal generics
Dissolution/permeation correlation for modified-release parenteral generics

FAQ

Common questions about non-oral in vitro release and permeability testing

Answers to typical inquiries regarding method selection, sample requirements, and regulatory use.

Our platform supports a broad range of non-oral formulations including topical creams, ointments, gels, transdermal patches, buccal films, ophthalmic solutions, nasal sprays, and parenteral depot systems (microspheres, liposomes, in situ gels). Each formulation type requires a tailored method design, which is scoped during initial consultation.
We typically use HPLC-UV or LC-MS/MS for quantitation, depending on the drug's physicochemical properties and required sensitivity. Method development follows ICH guidelines and includes specificity, linearity, precision, and recovery validation. For highly potent or poorly UV-absorbing compounds, LC-MS/MS is preferred.
For poorly soluble compounds, we optimize the receptor medium with appropriate co-solvents or surfactants to maintain sink conditions without harming the membrane integrity. Alternative approaches such as sample-and-separate or continuous flow cells can also be applied. All modifications are documented and evaluated for their impact on release kinetics.
Yes, our study reports are designed to align with FDA and EMA expectations for in vitro release and permeation data. We follow the relevant guidance documents (e.g., SUPAC-SS, FDA IVRT guidance) and provide a clear description of method validation, experimental conditions, and data interpretation. Each project's suitability for a specific regulatory pathway is discussed during scoping.
Turnaround time is project-dependent and defined during scoping. We aim to provide an initial study plan within one week of receiving formulation samples and target compound information. Execution timelines depend on method development complexity and number of test conditions.
Yes, we can support the generation of in vitro release and permeation data that may be used for IVIVC modeling. However, the correlation itself is typically performed by the client or a partner modeling team. We provide the raw in vitro results, including detailed time-point profiles, necessary for such analysis.

Scientific Literature

References

Takahashi Y, Kambayashi A. Physiologically based in vitro - in vivo correlation of modified release oral formulations with non-linear intestinal absorption: A case study using mirabegron. European journal of pharmaceutics and biopharmaceutics: official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V. 2024;204:114479. View on PubMed
Wang CC, Chen YL, Lu TC, et al. Design and evaluation of oral formulation for apixaban. Heliyon. 2023;9(8):e18422. View on PubMed

Please kindly note that our products and services are for research use only.